Sharon Janet Bruce Hanley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sharon Janet Bruce Hanley has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Etsuko Miyagi
Department of Obstetrics and Gynecology, Yokohama City University Graduate School of Medicine
5 shared publications - Masayuki Sekine
Department of Obstetrics and Gynecology, Graduate School of Medical Science, University of the Ryukyus, 1076 Kiyuna, Ginowan, Okinawa 901-2720, Japan
5 shared publications Noriaki Sakuragi
Women's Healthcare Center, Otaru General Hospital, Otaru, Japan
5 shared publications- Takayuki Enomoto
Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
5 shared publications - Yutaka Ueda
Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Japan
5 shared publications - Asami Yagi
Wakayama Medical University
4 shared publications
Latest Publications
- Open Access
- 19 June 2025
- Published by Center for Open Science in OSF Preprints
Determinants of Human Papillomavirus Vaccination Decision-Making in Japan: A Narrative Literature Review Exploring Contextual, Social, and Adolescent-Specific Influences
【Background】Human papillomavirus (HPV) vaccination coverage in Japan was initially over 70%, but it dramatically declined following 2013 media reports of adverse events, leading to public fear and suspension of proactive government recommendations. Despite the resumption of the recommendations in 2022, public trust remains low, with 40.9% of girls and mothers still undecided about HPV vaccination. This review synthesises evidence on the determinants of HPV vaccination decision-making among caregivers and adolescent girls in Japan and identifies research gaps to guide future research. 【Methods】A literature search was conducted using three key topics: HPV vaccination, willingness, and adolescent girls or caregivers. Studies were selected, focusing on research that examined influences on HPV vaccination decision-making in Japan. Determinants were categorized using the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunisation vaccine hesitancy matrix.【Results】This review identified a wide range of determinants influencing HPV vaccination decision-making, including contextual, individual and group, and vaccine-specific factors. Contextual influences, such as government recommendations and negative media coverage, play a significant role in shaping public attitudes. Individual and group factors, including parental knowledge, healthcare provider recommendations, and peer norms, are also critical. Vaccine-specific issues, such as concerns about safety, cultural barriers, and inadequate sex education, further complicate decision-making.Three key gaps were also identified: (1) insufficient exploration of contextual influences, including Japan’s unique socio-cultural landscape and historical mistrust; (2) limited understanding of how adolescents navigate social group influences and integrate conflicting information into their decisions; and (3) a lack of focus on the specific perceptions of adolescent girls.【Conclusions】Addressing these gaps requires interdisciplinary research that incorporates socio-cultural, behavioural and systemic perspectives. Further research and tailored interventions are essential to rebuild public trust and increase HPV vaccine uptake in Japan.
- 19 June 2025
- Published by Center for Open Science in OSF Preprints
Open AccessDeterminants of Human Papillomavirus Vaccination Decision-Making in Japan: A Narrative Literature Review Exploring Contextual, Social, and Adolescent-Specific Influences
【Background】Human papillomavirus (HPV) vaccination coverage in Japan was initially over 70%, but it dramatically declined following 2013 media reports of adverse events, leading to public fear and suspension of proactive government recommendations. Despite the resumption of the recommendations in 2022, public trust remains low, with 40.9% of girls and mothers still undecided about HPV vaccination. This review synthesises evidence on the determinants of HPV vaccination decision-making among caregivers and adolescent girls in Japan and identifies research gaps to guide future research. 【Methods】A literature search was conducted using three key topics: HPV vaccination, willingness, and adolescent girls or caregivers. Studies were selected, focusing on research that examined influences on HPV vaccination decision-making in Japan. Determinants were categorized using the World Health Organization (WHO) Strategic Advisory Group of Experts on Immunisation vaccine hesitancy matrix.【Results】This review identified a wide range of determinants influencing HPV vaccination decision-making, including contextual, individual and group, and vaccine-specific factors. Contextual influences, such as government recommendations and negative media coverage, play a significant role in shaping public attitudes. Individual and group factors, including parental knowledge, healthcare provider recommendations, and peer norms, are also critical. Vaccine-specific issues, such as concerns about safety, cultural barriers, and inadequate sex education, further complicate decision-making.Three key gaps were also identified: (1) insufficient exploration of contextual influences, including Japan’s unique socio-cultural landscape and historical mistrust; (2) limited understanding of how adolescents navigate social group influences and integrate conflicting information into their decisions; and (3) a lack of focus on the specific perceptions of adolescent girls.【Conclusions】Addressing these gaps requires interdisciplinary research that incorporates socio-cultural, behavioural and systemic perspectives. Further research and tailored interventions are essential to rebuild public trust and increase HPV vaccine uptake in Japan.
- Open Access
- 12 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
A model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions
We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. We used three CC models to project the short- and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2-, or 5-year delay) versus no delay in the context of both cytology-based and human papillomavirus (HPV)-based screening. Models projected a relative increase in symptomatically detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard), and 170% higher (MISCAN-Cervix) for underscreened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen 3 years prior to disruption). Over a woman’s lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman’s last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners. Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect underscreened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions.
- 12 October 2022
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 11
Open AccessA model-based analysis of the health impacts of COVID-19 disruptions to primary cervical screening by time since last screen for current and future disruptions
We evaluated how temporary disruptions to primary cervical cancer (CC) screening services may differentially impact women due to heterogeneity in their screening history and test modality. We used three CC models to project the short- and long-term health impacts assuming an underlying primary screening frequency (i.e., 1, 3, 5, or 10 yearly) under three alternative COVID-19-related screening disruption scenarios (i.e., 1-, 2-, or 5-year delay) versus no delay in the context of both cytology-based and human papillomavirus (HPV)-based screening. Models projected a relative increase in symptomatically detected cancer cases during a 1-year delay period that was 38% higher (Policy1-Cervix), 80% higher (Harvard), and 170% higher (MISCAN-Cervix) for underscreened women whose last cytology screen was 5 years prior to the disruption period compared with guidelines-compliant women (i.e., last screen 3 years prior to disruption). Over a woman’s lifetime, temporary COVID-19-related delays had less impact on lifetime risk of developing CC than screening frequency and test modality; however, CC risks increased disproportionately the longer time had elapsed since a woman’s last screen at the time of the disruption. Excess risks for a given delay period were generally lower for HPV-based screeners than for cytology-based screeners. Our independent models predicted that the main drivers of CC risk were screening frequency and screening modality, and the overall impact of disruptions from the pandemic on CC outcomes may be small. However, screening disruptions disproportionately affect underscreened women, underpinning the importance of reaching such women as a critical area of focus, regardless of temporary disruptions.
- 25 July 2022
- Published by Elsevier in The Lancet Oncology
- Vol. 23 (8) , 972-973
Problems with catch-up HPV vaccination after resumption of proactive recommendations
- 25 July 2022
- Published by Elsevier in The Lancet Oncology
- Vol. 23 (8) , 972-973
Problems with catch-up HPV vaccination after resumption of proactive recommendations
- Open Access
- 11 July 2022
- Published by Wiley in Cancer Science
- Vol. 113 (9) , 3211-3220
Effectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity
Japanese girls aged 12–16 years are offered free human papillomavirus (HPV) vaccination and cervical cancer screening is conducted with cytology and not HPV testing from the age of 20 years. So far, no study has analyzed the effect of HPV vaccination against cervical precancers considering HPV infection status and sexual activity. We aimed to analyze the vaccine effectiveness (VE) against HPV infection and cytological abnormalities, adjusted for sexual activity. This study comprised women aged 20–26 years who underwent cervical screening in Niigata. We obtained HPV vaccination status from municipal records and a questionnaire along with information concerning sexual activity. Of 5194 women registered for this study, final analyses included 3167 women in the vaccinated group (2821 vaccinated women prior to sexual debut) and 1386 women in the unvaccinated group. HPV 16/18 (0.2% vs 3.5%), 31/45/52 (3.4% vs 6.6%), and 31/33/45/52/58 (5.0% vs 9.3%) positive rates were significantly lower in the vaccinated group (P < 0.001). No women vaccinated before sexual debut had HPV 16/18‐related cytological abnormalities. VE for HPV 16/18 infection and high‐grade cytological abnormalities in women vaccinated prior to sexual debut were 95.8% (95% CI 81.9–99.0%; P < 0.001) and 78.3% (95% CI 11.3–94.7%; P = 0.033), respectively, in multivariate analyses adjusted for age and number of sexual partners. However, analyses of all vaccinated women did not show significant effectiveness against cytological abnormalities. Our results showed the effectiveness of HPV vaccine against high‐grade cervical cytological abnormalities and the importance of the vaccination before sexual debut.
- 11 July 2022
- Published by Wiley in Cancer Science
- Vol. 113 (9) , 3211-3220
Open AccessEffectiveness of human papillomavirus vaccine against cervical precancer in Japan: Multivariate analyses adjusted for sexual activity
Japanese girls aged 12–16 years are offered free human papillomavirus (HPV) vaccination and cervical cancer screening is conducted with cytology and not HPV testing from the age of 20 years. So far, no study has analyzed the effect of HPV vaccination against cervical precancers considering HPV infection status and sexual activity. We aimed to analyze the vaccine effectiveness (VE) against HPV infection and cytological abnormalities, adjusted for sexual activity. This study comprised women aged 20–26 years who underwent cervical screening in Niigata. We obtained HPV vaccination status from municipal records and a questionnaire along with information concerning sexual activity. Of 5194 women registered for this study, final analyses included 3167 women in the vaccinated group (2821 vaccinated women prior to sexual debut) and 1386 women in the unvaccinated group. HPV 16/18 (0.2% vs 3.5%), 31/45/52 (3.4% vs 6.6%), and 31/33/45/52/58 (5.0% vs 9.3%) positive rates were significantly lower in the vaccinated group (P < 0.001). No women vaccinated before sexual debut had HPV 16/18‐related cytological abnormalities. VE for HPV 16/18 infection and high‐grade cytological abnormalities in women vaccinated prior to sexual debut were 95.8% (95% CI 81.9–99.0%; P < 0.001) and 78.3% (95% CI 11.3–94.7%; P = 0.033), respectively, in multivariate analyses adjusted for age and number of sexual partners. However, analyses of all vaccinated women did not show significant effectiveness against cytological abnormalities. Our results showed the effectiveness of HPV vaccine against high‐grade cervical cytological abnormalities and the importance of the vaccination before sexual debut.
- Open Access
- 30 May 2022
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 24, 100480
Impact of the COVID-19 pandemic on suicide rates in Japan through December 2021: An interrupted time series analysis
- 30 May 2022
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 24, 100480
Open AccessImpact of the COVID-19 pandemic on suicide rates in Japan through December 2021: An interrupted time series analysis
- Open Access
Long-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review
The preventive effect of HPV vaccines against anogenital and oropharyngeal cancers has been proven in both clinical trials and real-world data. We reviewed the published evidence about the long-term efficacy and effectiveness of the HPV vaccine in available papers of clinical trials and real-world data. As far as we searched, the longest period of preventive effect for the bivalent, 4-valent, and 9-valent vaccine were 11 years in the Costa Rica trial, 14 years in the FUTURE II, and 8 years in the LTFU extension study of V503-002 and the Scandinavian study, respectively. The sustained clinical effect during the observation period was longest for the 4-valent vaccine. In real-world data, the longest observation period of the vaccine effectiveness was 12 years in an Australian study for the 4-valent vaccine. On the other hand, the longest period of long-term persistence of HPV vaccine-induced seropositivity was 14 years in FUTURE II for the 4-valent vaccine. For the bivalent vaccine, additional long-term follow-up studies may not have been planned due to the launch of the 4-valent and 9-valent vaccines. In some studies of the 9-valent vaccine, the results have not yet been published because of the short observation period. The additional results are expected in the future. In a national immunization program, most girls and boys are inoculated with HPV vaccine by the time puberty begins; thus, it is important to monitor the vaccine effect at least until the sexually active period in their 20s and 30s.
Open AccessLong-Term Effects of Human Papillomavirus Vaccination in Clinical Trials and Real-World Data: A Systematic Review
The preventive effect of HPV vaccines against anogenital and oropharyngeal cancers has been proven in both clinical trials and real-world data. We reviewed the published evidence about the long-term efficacy and effectiveness of the HPV vaccine in available papers of clinical trials and real-world data. As far as we searched, the longest period of preventive effect for the bivalent, 4-valent, and 9-valent vaccine were 11 years in the Costa Rica trial, 14 years in the FUTURE II, and 8 years in the LTFU extension study of V503-002 and the Scandinavian study, respectively. The sustained clinical effect during the observation period was longest for the 4-valent vaccine. In real-world data, the longest observation period of the vaccine effectiveness was 12 years in an Australian study for the 4-valent vaccine. On the other hand, the longest period of long-term persistence of HPV vaccine-induced seropositivity was 14 years in FUTURE II for the 4-valent vaccine. For the bivalent vaccine, additional long-term follow-up studies may not have been planned due to the launch of the 4-valent and 9-valent vaccines. In some studies of the 9-valent vaccine, the results have not yet been published because of the short observation period. The additional results are expected in the future. In a national immunization program, most girls and boys are inoculated with HPV vaccine by the time puberty begins; thus, it is important to monitor the vaccine effect at least until the sexually active period in their 20s and 30s.
- Open Access
- 31 January 2022
- Published by Wiley in Cancer Science
- Vol. 113 (4) , 1435-1440
Long‐term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real‐world data
In Japan, public funding for HPV vaccination began in 2010 for girls aged 13–16 years (birth cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long‐term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25–26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993–1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92–109 months). The HPV high‐risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross‐protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long‐term 9‐year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.
- 31 January 2022
- Published by Wiley in Cancer Science
- Vol. 113 (4) , 1435-1440
Open AccessLong‐term effectiveness of HPV vaccination against HPV infection in young Japanese women: Real‐world data
In Japan, public funding for HPV vaccination began in 2010 for girls aged 13–16 years (birth cohort years 1994–1997) and women born in 1994 who turned 25 in 2019. We aimed to verify the long‐term effectiveness of the bivalent HPV vaccine in women aged 25 years. Subjects were women aged 25–26 years who underwent cervical cancer screening and HPV testing in Niigata from 2019 to 2020 (birth cohort years 1993–1994). Information on vaccination status and sexual behavior was obtained from a questionnaire and municipal records. We compared the HPV infection rates of the vaccinated and unvaccinated groups. Of the 429 registrants, 150 (35.0%) and 279 (65.0%) were vaccinated and unvaccinated, respectively. The average period from HPV vaccination to HPV testing was 102.7 months (8.6 years), with a median of 103 months (range 92–109 months). The HPV high‐risk infection rate was 21.3% (32/150) in the vaccinated group and 23.7% (66/279) in the unvaccinated group (P = 0.63). The HPV16/18 infection rate was 0% (0/150) in the vaccinated group and 5.4% (15/279) in the unvaccinated group, showing a significant difference (P = 0.0018), and the vaccine effectiveness was 100%. The cross‐protective type HPV31/45/52 infection rate in the vaccinated group was significantly lower than that in the unvaccinated group (3.3% vs. 10.0%, P = 0.013). There was no significant difference in the mean age at sexual debut and the number of previous sexual partners between the two groups. We have demonstrated the long‐term 9‐year effectiveness of the bivalent vaccine against HPV infection for the first time in Japan.
- Open Access
Internet Survey of Awareness and Behavior Related to HPV Vaccination in Japan
Recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears in Japan. We aimed to clarify the differences between vaccinated and unvaccinated females in their awareness, knowledge, and behaviors toward cervical cancer, HPV vaccination and sex. Questionnaires were administered online to women aged 16 to 20. We conducted investigations for the following: awareness, knowledge, and actions for cervical cancer, HPV vaccination, and sexual activity, as well as items related to participants’ social background. The survey in 828 girls revealed three points. The first is that more than half of the surveyed Japanese girls had poor knowledge about cervical cancer screening, HPV, or HPV vaccines. The second is that those in the unvaccinated group had a particularly poor knowledge of the subject and tended to have higher sexual activity. The final is that only 0.5% of the girls experienced changes in awareness about sexual activity after vaccination. In conclusion, this is the first large-scale survey analyzing the association between HPV vaccination and sexual activity in Japanese girls. Not only do unvaccinated girls not benefit from vaccines, but they also tend to engage in high-risk sexual behavior, and thus it is even more important to provide information on the effectiveness of vaccines and the usefulness of cancer screening.
Open AccessInternet Survey of Awareness and Behavior Related to HPV Vaccination in Japan
Recommendations for HPV vaccines were suspended in 2013 due to unfounded safety fears in Japan. We aimed to clarify the differences between vaccinated and unvaccinated females in their awareness, knowledge, and behaviors toward cervical cancer, HPV vaccination and sex. Questionnaires were administered online to women aged 16 to 20. We conducted investigations for the following: awareness, knowledge, and actions for cervical cancer, HPV vaccination, and sexual activity, as well as items related to participants’ social background. The survey in 828 girls revealed three points. The first is that more than half of the surveyed Japanese girls had poor knowledge about cervical cancer screening, HPV, or HPV vaccines. The second is that those in the unvaccinated group had a particularly poor knowledge of the subject and tended to have higher sexual activity. The final is that only 0.5% of the girls experienced changes in awareness about sexual activity after vaccination. In conclusion, this is the first large-scale survey analyzing the association between HPV vaccination and sexual activity in Japanese girls. Not only do unvaccinated girls not benefit from vaccines, but they also tend to engage in high-risk sexual behavior, and thus it is even more important to provide information on the effectiveness of vaccines and the usefulness of cancer screening.
- Open Access
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (6)
Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study
Hanley SJ, et al. J Gynecol Oncol. 2021 Sep;32:e86. https://doi.org/10.3802/jgo.2021.32.e86
- 1 January 2021
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 32 (6)
Open AccessEvaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study
Hanley SJ, et al. J Gynecol Oncol. 2021 Sep;32:e86. https://doi.org/10.3802/jgo.2021.32.e86